Skip to content

AdaptDx Research

Landmark AMD Study Relies on AdaptDx

Researchers at the University of Alabama School of Medicine conducted the Alabama Study on Early Age-Related Macular Degeneration (ALSTAR) to investigate the relationship between dark adaptation and AMD. Using AdaptDx®—which detects AMD with 90.6% accuracyii—they were able to determine dark adaptation is the first biomarker of AMD and that this functional symptom indicates subclinical AMD at least three years before structural changes are visible.ii The much-referenced ALSTAR Study was led by Cynthia Owsley, PhD, and published in Ophthalmology.

0281-library

Peer-Reviewed Publications

Confidence in the sensitivity and specificity of AdaptDx has led to more than 30 peer-reviewed publications.

Partners in Research

Leading institutions have used AdaptDx for research and education, including:

University of Alabama in Birmingham
Harvard University
University of Copenhagen
Nova Southwestern University
Penn State Hershey
National Eye Institute
Ohio State University College of Optometry
Keck School of Medicine of University of Southern California
Massachusetts College of Pharmacy and Health Sciences
Duke Eye Center
University of Michigan
STREETlab
Institut Macula Retina
Queen's University of Belfast
Taipei Medical Univesity Hospital
University of Ulster
WillsEye Hospital
Moorfields Eye Hospital
Lahey Hospital & Medical Center
University of Iowa
University of Wisconsin

Major Study Participation

AdaptDx was chosen as a clinical endpoint in two current multi-year international studies of macular degeneration—MACUSTAR and ARIS.

MACUSTAR

The AdaptDx was selected as a key testing device in the MACUSTAR project, a five-year study aimed at reducing the disease burden of AMD worldwide. Currently funded with more than 16 million euros from the European Union and leading European pharmaceutical companies, the investigation expects to enroll 750 patients in seven countries across Europe.

The research project will be conducted at 20 clinical study centers in Europe, including:

  • University Eye Clinic Bonn and the GRADE Reading Center Bonn
  • Moorfields Eye Hospital
  • University College
  • City University
  • Fondation voir et entendre Paris
  • Coimbra Association for Innovation and Biomedical Research on Light and Image (AIBILI)
  • Radound University Medical Center
  • University of Sheffield
  • European Clinical Research Infrastructures Network (ECRIN) Paris

AMD Ryan Initiative Study (ARIS):
Led by the National Eye Institute

This clinical study will follow 500 people over five years to learn more about the natural history of early age-related macular degeneration (AMD). Researchers will use the latest technologies, including AdaptDx, to measure function and visualize structures within the eye. The hope is to identify biomarkers of disease progression well before it advances to late-stage disease and causes vision loss.

All ARIS participants will undergo routine spectral domain optical coherence tomography (SD-OCT); and visual function will be measured by dark-adapted fundus perimetry and dark adaption. Dark-adaptation studies are relevant because AMD tends to first damage rod photoreceptors (the retinal cells that allow for vision under dim conditions) earlier than it does cone photoreceptors, which enable daylight vision. Researchers at each of the 20 ARIS study sites will track drusen volume changes as well as other findings on SD-OCT to see if they correspond to functional changes in visual acuity and dark adaptation.

When I look at the future of managing macular degeneration, I see the AdaptDx as the essential tool in AMD management just as now I see the OCT as the essential tool in managing glaucoma in its earliest stages. By finding a disease early, and intervening appropriately we have the best chance of altering the course.

Thomas Henderson Thomas Henderson, MD View all testimonials
0256-camera

Videos

Eye care professionals demonstrate how the AdaptDx benefits their practices.

0431-laptop-phone

Webinars

MacuLogix clinical advisers demonstrate how AdaptDx can improve patient outcomes.

0277-book2

E-Books

Evidence-based guides include the latest information on AMD classification, diagnosis, staging and treatment.

Learn about the Benefits of AdaptDx

AMD Detection with AdaptDx

The AdaptDx testing tool from MacuLogix offers you the chance to diagnose AMD in patients before vision loss occurs.

Contact Our Sales Team

As the AMD experts, our sales team is here to answer your questions about the clinical and financial benefits of the AdaptDx.